Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus
Open Access
- 1 May 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 17 (5) , 1169-1178
- https://doi.org/10.1158/1055-9965.epi-07-2852
Abstract
Background: Frequent consumption of aspirin and nonsteroidal anti-inflammatory drugs (NSAID) has been associated with reduced occurrence of cancers of the esophagus, although potential modifying effects of other causal factors remain relatively unexplored. Methods: We compared nationwide samples of Australian patients with adenocarcinomas of the esophagus (EAC; n = 367) or esophagogastric junction (EGJAC; n = 426) or esophageal squamous cell carcinoma (ESCC; n = 309) with control participants sampled from a population register (n = 1,580). Intakes of aspirin, other NSAIDs, and acetaminophen (paracetamol) were assessed from self-reports. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) using multivariable logistic regression. Results: Compared with never-users of aspirin, those who used aspirin at least weekly had significantly lower risks of EAC (OR, 0.48; 95% CI, 0.32-0.72), EGJAC (OR, 0.71; 95% CI, 0.49-1.01), and ESCC (OR, 0.63; 95% CI, 0.40-0.98). At least weekly use of other NSAIDs was also associated with reduced risks of EAC (OR, 0.74; 95% CI, 0.51-1.08), EGJAC (OR, 0.53; 95% CI, 0.37-0.77), and ESCC (OR, 0.46; 95% CI, 0.30-0.73). No association was observed between frequent use of acetaminophen and esophageal cancer. Risk reductions for EAC among users of aspirin and NSAIDs were greater among those who experienced at least weekly symptoms of reflux (OR, 0.26; 95% CI, 0.12-0.55 and OR, 0.41; 95% CI, 0.21-0.77, respectively) than those who did not experience reflux (OR, 0.96; 95% CI, 0.46-2.00 and OR, 0.78; 95% CI, 0.35-1.72, respectively). Recent use of NSAIDs in the past 5 years was associated with greater risk reductions. Conclusions: Frequent use of aspirin and NSAIDs is associated with reduced occurrence of esophageal cancers, particularly among those with frequent symptoms of gastroesophageal reflux. (Cancer Epidemiol Biomarkers Prev 2008;17(5):1169–9)Keywords
This publication has 53 references indexed in Scilit:
- OUTCOMES AFTER OESOPHAGOGASTRECTOMY FOR CARCINOMA OF THE OESOPHAGUSAnz Journal of Surgery, 2007
- Risk of Squamous Cell Carcinoma of the Upper Aerodigestive Tract in Cancer-Free Alcoholic Japanese Men: An Endoscopic Follow-up StudyCancer Epidemiology, Biomarkers & Prevention, 2006
- Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence baseBMJ, 2006
- Regular aspirin use and esophageal cancer riskInternational Journal of Cancer, 2006
- Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skinJournal of the American Academy of Dermatology, 2005
- Outcome of oesophagectomy for adenocarcinoma of the oesophagus and oesophagogastric junctionAnz Journal of Surgery, 2005
- Overweight, obesity and cancer: epidemiological evidence and proposed mechanismsNature Reviews Cancer, 2004
- Obesity and Mortality from CancerNew England Journal of Medicine, 2003
- Smoking and colorectal adenomasEuropean Journal Of Cancer Prevention, 2000
- Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers.Gut, 1996